FDA Elevates Cema-Cel’s First-Line LBCL Path

Company Allogene Therapeutics Event Type Regulatory Designation (RMAT and Fast Track) Modality Allogeneic anti-CD19 CAR-T cell therapy Asset Cemacabtagene ansegedleucel (cema-cel) Target CD19 Disease Area MRD-positive large B-cell lymphoma (LBCL) after first-line therapy Summary FDA granted Regenerative Medicine Advanced Therapy and Fast Track designations to…